Exchange: NASDAQ·Updated 03:14 PM EDT

VRTX News

News
all
press releases
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.read more...
Benzinga
More News
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
Stocktwits
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Zacks
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Zacks
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45...
Business Wire
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
Zacks
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
Zacks
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the...
Business Wire
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAmgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally...
Nasdaq News: Markets
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Key PointsVertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas...
Nasdaq News: Markets

Advertisement|Remove ads.